Skip to main content
OpenTrials
Completed

NCT Number: NCT02553356

PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers

This Phase 1, single-dose study will be conducted in adult female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of PT2385 Tablets. The study will consist of two periods and will be conducted in a crossover fashion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Spaulding Clinical

West Bend, Wisconsin, United States

About this study

Subjects will be randomized in equal numbers to two sequences of meal conditions (fasting and non-fasting). Serial blood samples will be collected for after dose administration in each period. Subjects will be confined at the clinical research for a portion of each period.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female between 18 and 45 years of age;
  • If of childbearing potential, willing to practice methods of birth control;
  • If of childbearing potential, must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment into the trial;
  • Has a body mass index (BMI) between 19 and 32 kg/m2;
  • Willing and able to give written informed consent for study participation and provide consent for access to medical data;
  • Willing and able to cooperate with all aspects of the protocol.

Exclusion criteria

  • Any vaccination within 30 days before start of this study and throughout the study;
  • Use of or need for any systemic drug(s) including vitamins or herbal preparations other than drugs used for contraception, within 30 days before entry into the study or during the study;
  • Use of aspirin, non-steroidal anti-inflammatory agents, or acetaminophen within 5 days prior to the ingestion of the study drug;
  • Donation or receipt of blood or blood components within the 4 weeks prior to the start of the study;
  • Any diagnostic or intervention procedure requiring a contrast agent within the 30 days prior to the start of study participation;
  • Abnormal blood pressure or pulse rate;
  • Abnormal screening electrocardiogram (ECG);
  • Use of tobacco or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, etc.);
  • Consumption of alcohol or xanthine-containing products;
  • Consumption of grapefruit, star fruit, Seville oranges, or products containing any of these ingredients;
  • Receipt of any investigational agent within 30 days;
  • A positive history of drug abuse or a positive test result for drug(s) of abuse;
  • Female subjects who are planning a pregnancy or are pregnant or lactating.

Treatment and study plan

PT2385

Drug

Primary outcomes

  1. Effect of food on the pharmacokinetics of a single dose of PT2385 Tablets administered to normal healthy adult subjects (Cmax).

    Time frame: 6 days

    Peak Plasma Concentration (Cmax) will be assessed in both the fasting and non-fasting conditions and compared.

Secondary outcomes

  1. Safety and tolerability of PT2385 Tablets in normal healthy adult subjects by reviewing the incidence of treatment-emergent adverse events.

    Time frame: 30 days

    Analyses will consist of data summaries for AEs/SAEs

  2. Pharmacodynamic (PD) effects of treatment with PT2385 Tablets (plasma levels).

    Time frame: 6 days

    Variability in biomarkers will be correlated with plasma levels of PT2385.

Sponsors and collaborators

Lead sponsor

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Industry

Registry information

Official study title

A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2385 Tablets

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Sep 17, 2015
Registry last updated
Dec 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.